Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr

Lupin is the 6th largest company in the Indian Pharmaceutical Market

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate

This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.

Ascentage Pharma and Tanner Pharma Group initiate a global innovative named Patient Program

Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.

SMS Pharmaceuticals receives approval for Ibuprofen by EDQM

With this, the company can start selling Ibuprofen in the European markets.

WuXi AppTec plans to build a new site in Singapore

Better serving global partners and advancing healthcare innovation

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA

ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.

Syngene signs 10-year biologics manufacturing agreement with Zoetis

Syngene's collaboration with Zoetis started in 2011